Acetylator phenotype in diabetic neuropathy.

McLaren, E H; Burden, A C; Moorhead, P J

doi:10.1136/bmj.2.6082.291

Cited by 39 publications

(18 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whatever the reason for the increased incidence of fast acetylators our findings on neuropathy are at variance with those of McLaren et al [7] and the discrepant results need an explanation. We suggest that McLaren et al [7] may have misinterpreted their findings when they concluded that there was a higher proportion of fast acetylators in patients without neuropathy.…”

Section: Discussioncontrasting

confidence: 57%

“…This was the case in spite of the fact that, in our control population, the prevalence of fast acetylators (48%) was considerably higher than that reported for the British population (37%) [12]. In contrast to the results of McLaren et al [7], there was no significant association between acetylator status and diabetic neuropathy.…”

Section: Discussioncontrasting

confidence: 56%

“…We suggest that McLaren et al [7] may have misinterpreted their findings when they concluded that there was a higher proportion of fast acetylators in patients without neuropathy. Thus if fast acetylators have a higher than normal incidence of Type 1 but not of Type 2 diabetes and neuropathy is equally distributed between the two types of diabetes, there would be a preponderance of Type 1 fast acetylators without neuropathy.…”

Section: Discussionmentioning

confidence: 66%

“…If the first statement is true, then acetylator status might be an additional genetic marker for diabetes. Bodansky et al [9] combined the data from previous studies [6,7] with those from 55 Type I diabetic patients from their own clinic and found an increased frequency of fast acetylators. They suggested that fast acetylator phenotype is a genetic marker for Type 1 diabetes and that more than one genetic locus may therefore be involved in susceptibility to Type 1 diabetes.…”

mentioning

confidence: 99%

“…Slow acetylators are more prone than fast acetylators to develop peripheral neuropathy when treated with isoniazid [4,5] and a study from Finland found that seven out of nine Type I (insulin-dependent) diabetic children were fast acetylators [6]. McLaren et al therefore investigated acetylator status in relation to diabetic neuropathy [7]. They found that diabetic patients without peripheral neuropathy had a significantly higher proportion of fast acetylators than a control group.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Acetylator status and diabetic neuropathy

1982

View full text Add to dashboard Cite

Summary.Acetylator status was determined in 112 normal and 116 diabetic subjects. Forty-eight percent of the normal subjects were fast acetylators compared with 74% of the Type 1 (insulin-dependent) diabetic and 54% of the Type 2 (non-insulin-dependent) diabetic subjects. This result for Type 1 diabetic patients was significantly different from the normal subjects, while that for Type 2 patients was intermediate between the two. In contrast to a previous report, there was no significant association of acetylator status with peripheral neuropathy in subjects with either Type 1 or Type 2 diabetes. Acetylator status could be a genetic marker for Type 1 diabetes, but the increased proportion of fast acetylators in both groups suggested the possibility of an artefact due to high glucose levels. The rate of acetylation of sulphadimidine was significantly greater in both fast and slow acetylators with diabetes compared with normal subjects and there was a significant association between high plasma glucose and acetylator status. Prospective studies will be necessary to confirm whether acetylator status is a true genetic marker for diabetes.

show abstract

Section: Discussioncontrasting

confidence: 57%

Section: Discussioncontrasting

confidence: 56%

Section: Discussionmentioning

confidence: 66%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Acetylator status and diabetic neuropathy

1982

View full text Add to dashboard Cite

show abstract

N‐acetyltransferase 2 polymorphism in patients with Diabetes Mellitus

Yalın

Hatungil

Tamer

et al. 2006

Cell Biochemistry & Function

View full text Add to dashboard Cite

The arylamine N-acetyltransferases (NATs) are a unique family of enzymes that catalyse the transfer of an acetyl group from acetyl-CoA to the terminal nitrogen of hydrazine and arylamine drugs and carcinogens. Human arylamine NATs are known to exist as two isoenzymes, NAT1 and NAT2. The objective of this study was to identify whether the genetic polymorphism of NAT2 plays a role in susceptibility to Diabetes Mellitus (DM). Ninety-seven patients with DM and 104 healthy controls were enrolled in the study. NAT2*5A, NAT2*6A, NAT2*7A/B and NAT2*14A polymorphisms were detected by using real time PCR with LightCycler (Roche Diagnostics GmbH, Mannheim, Germany). According to our data, the NAT2*5A and NAT2*6A mutant genotypes and NAT2*14A heterozygous genotype were associated with an increased risk of development of DM (OR = 47.06; 95%CI: 10.55-209.77 for NAT 2*5A, OR = 18.48; 95%CI: 3.83-89.11 for NAT2*6A and OR = 18.22; 95%CI: 6.29-52.76 for NAT2*14A). However, the NAT2*7A/B gene polymorphism carried no increased risk for developing DM disease. After grouping according to phenotypes as either slow or fast acetylators, NAT2*6A slow acetylator was found to be a significant risk factor for DM (OR = 6.09; 95%CI: 1.99-18.6, p = 0.02). The results indicate that NAT2 slow acetylator genotypes may be an important genetic determinant for DM in the Turkish population.

show abstract

Dr. N‐Acetylation Polymorphism and Diabetes Mellitus among Saudi Arabians

El-Yazigi¹,

Johansen²,

Raines³

et al. 1992

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The acetylator phenotypes of 200 Saudi diabetics and an equal number of control subjects of the same origin were determined by measuring the peak height ratio of two urinary caffeine metabolites, 5-acetylamino-6-formylamino-3-methyluracil (AFMU) and 1-methylxanthine (1MX), using a simplified high-performance liquid chromatographic method. Urine samples were collected from the diabetics and the control subjects who regularly drink coffee, tea, or caffeinated beverages as part of their normal daily diet. The patients were classified as either type 1 (insulin-dependent) (28 patients) or type 2 (insulin-independent) diabetics (172 patients) according to standard criteria. The reproducibility of acetylator phenotype was established by examining the peak height ratio of AFMU/1MX in 18 diabetics and 6 control subjects on different days. Significant differences in the proportion of rapid acetylators were observed between type 1 (53.6%) and type 2 (33.7%) diabetics (P < or = .0436), and between the control group (26%) and the overall diabetics (36.5%) (P < or = .024) or those with type 1 disease (P < or = .0028). Also, there was a significant (P < or = .0436) association between rapid acetylator status and type 1 diabetes mellitus.

show abstract

Acetylator phenotype in diabetic neuropathy.

Cited by 39 publications

References 5 publications

Acetylator status and diabetic neuropathy

Acetylator status and diabetic neuropathy

N‐acetyltransferase 2 polymorphism in patients with Diabetes Mellitus

Dr. N‐Acetylation Polymorphism and Diabetes Mellitus among Saudi Arabians

Contact Info

Product

Resources

About